Long‐Term Efficacy and Outcomes of Endovascular Interventions in Budd‐Chiari Syndrome—A Real World Analysis
Liver International · 2026-05 · 46 (5)
DOI: 10.1111/liv.70638 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver International, online erschienen am 08.04.2026. Verfasst von Amar Mukund und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Liver and Biliary Sciences, New Delhi, India. Hauptthemen laut MEDLINE: Budd-Chiari Syndrome, Endovascular Procedures. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Purpose
To evaluate the long‐term safety, efficacy, and clinical outcomes of endovascular interventions [hepatic vein/inferior vena cava recanalization and Direct Intrahepatic Portosystemic Shunt (DIPS)] in patients with Budd‐Chiari Syndrome (BCS).
Methods
We retrospectively analysed electronic medical records of consecutive BCS patients who underwent endovascular interventions between 2010 and 2022 with at least 2 years of follow‐up. We analysed laboratory and clinical parameters, types of interventions, patency rates, and survival outcomes.
Results
Of 415 BCS patients, 161 patients underwent endovascular interventions (median age 33.06 (5–75) years, male‐to‐female ratio 2.2:1). 103 patients who underwent hepatic vein/inferior vena cava recanalization (angioplasty/stenting) and 58 patients who underwent DIPS. The DIPS group had higher baseline median Child‐Turcotte‐Pugh (CTP) score (8.27), MELD score (14.94) and Rotterdam score (0.96). The recanalization group had baseline CTP score (6.95), MELD score (13.01) and Rotterdam score (0.56). Both interventions resulted in significant improvements in clinical outcomes (ascites resolution and prevention of rebleeding) and ALBI grades ( p < 0.01). The DIPS group had persistently higher MELD and ALBI scores ( p < 0.05) and required more repeat endovascular interventions (58.6%). The recanalization group required fewer repeat interventions (7.7%). Patency rates at 1 and 5 years were 96% and 92% for recanalization, 82% and 45% for DIPS, and 100% and 60% for DIPS revisions, respectively. The 10‐year survival rate was 92% for the recanalization group and 88% for the DIPS group.
Conclusion
Endovascular interventions provide higher rates of symptom resolution and excellent long‐term overall survival in BCS patients. Patients undergoing DIPS exhibited persistently higher severity scores and a higher need for repeat interventions, consistent with a more severe disease phenotype at baseline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Institute of Liver and Biliary Sciences, New Delhi, India.
ORCID-Profile: Ankur Jindal, Shiv Kumar Sarin
Zitieren
APA
Mukund, A., Thakur, V., Jindal, A., Patidar, Y., Maiwall, R., & Sarin, S. K. (2026). Long‐Term Efficacy and Outcomes of Endovascular Interventions in Budd‐Chiari Syndrome—A Real World Analysis. Liver International, 46(5). https://doi.org/10.1111/liv.70638
Vancouver
Mukund A, Thakur V, Jindal A, Patidar Y, Maiwall R, Sarin SK. Long‐Term Efficacy and Outcomes of Endovascular Interventions in Budd‐Chiari Syndrome—A Real World Analysis. Liver International. 2026;46(5). doi:10.1111/liv.70638
BibTeX
@article{Mukund2026,
author = {Mukund, Amar and Thakur, Vaibhav and Jindal, Ankur and Patidar, Yashwant and Maiwall, Rakhi and Sarin, Shiv Kumar},
title = {Long‐Term Efficacy and Outcomes of Endovascular Interventions in Budd‐Chiari Syndrome—A Real World Analysis},
journal = {Liver International},
year = {2026},
volume = {46},
number = {5},
doi = {10.1111/liv.70638}
}
EUVIMED